When generating antibodies for a target is more than routine (T 0435/20)
http://ipkitten.blogspot.com/2023/04/when-generating-antibodies-for-target.html The patent case law in Europe and the US diverges on the question of how routine it is to find new antibodies for a known target. In the US, claims directed to a group of antibodies functionally defined by the sequence of their target (so-called epitope claims), generally fall... Continue reading